CD274 and neoplasm: Atezolizumab is an Fc-engineered, humanized, monoclonal IgG1 antibody that selectively binds to programmed death-ligand 1 (PD-L1) and inhibits its interactions with PD-1 and B7.1 receptors causing T-cells more sensitive to the tumor.